与PIGC相关的脑病变:从18名新受试者身上学到的经验教训
Allan Bayat1,2, Maria Carla Borroto3, Smrithi Salian3
1Department of Pediatrics, Danish Epilepsy Center, Dianalund, Denmark. abaya@filadelfia.dk.
European journal of human genetics : EJHG
|September 17, 2025
概括
在PIGC的双变体导致严重的神经发育障碍与难治性和早期死亡率. 这项研究证实,PIGC变种破坏了糖酸氨基醇定蛋白质生物合成.
科学领域:
- 遗传学 遗传学 是一个
- 神经发育障碍 神经发育障碍
- 生物化学 生物化学
背景情况:
- PIGC基因对于糖酸氨基醇固蛋白 (GPI-AP) 生物合成至关重要.
- 以前的报道将双性PIGC变体与发育迟缓,智力障碍和联系在一起.
研究的目的:
- 描述PIGC致病变体的临床和生物分子特征.
- 扩大对与PIGC相关的神经发育障碍的理解.
主要方法:
- 建立了一个18个未报告的PIGC变异的试验对象队列.
- 通过基因组/外基因组测序收集的临床数据和识别的变异.
- 用于模拟 (AlphaFold2) 和流细胞计用于GPI-AP分析.
主要成果:
- 在试验者中发现了严重的神经发育障碍,包括认知障碍,抗治疗的发作和10/18个人的过早死亡.
- 在受影响的个体中观察到脑成像异常,低血压和骨异常.
- 在试验样本和细胞模型中确认了细胞表面GPI-AP水平的降低.
结论:
- 双性PIGC变异与耐火性发作,严重发育障碍和儿童死亡率有关.
- 功能障碍的PIGC导致GPI-AP生物合成有缺陷.
- 这项研究扩大了PIGC相关疾病的表型谱和分子理解.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.6K
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
11.4K
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
